HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy

HUTCHMED announced an exclusive license for HMPL-A830, a first-in-class KRAS-EGFR antibody-targeted therapy conjugate (ATTC), with expected clinical trial entry in H2 2026. The update is a forward-looking pipeline milestone that modestly improves the company’s development outlook, but it is not near-term commercial/clinical data.